公开(公告)号：US08436009B2

公开(公告)日：2013-05-07

申请号：US13695665

申请日：2011-05-18

申请人： Richard Clark ,  Fumiyoshi Matsuura ,  Masanobu Shinoda ,  Shinsuke Hirota ,  Kazunobu Kira ,  Hiroshi Azuma ,  Atsushi Takemura ,  So Yasui ,  Kazutomi Kusano ,  Masaki Mikamoto ,  Takao Omae

发明人： Richard Clark ,  Fumiyoshi Matsuura ,  Masanobu Shinoda ,  Shinsuke Hirota ,  Kazunobu Kira ,  Hiroshi Azuma ,  Atsushi Takemura ,  So Yasui ,  Kazutomi Kusano ,  Masaki Mikamoto ,  Takao Omae

IPC分类号： A61K31/506 ,  C07D239/42

CPC分类号： C07D401/14 ,  C07D403/04

摘要： By oral administration of a compound represented by the following Formula (I): the blood level of Compound (IV): which has an excellent inhibitory action against blood coagulation factor VIIa and the anticoagulant action, reaches a level sufficient for expression of its pharmacological actions. Therefore, the compound of the present invention is useful as a therapeutic and/or prophylactic agent for diseases caused by thrombus formation.

摘要翻译： 通过口服给药由下式（I）表示的化合物：对血液凝固因子VIIa具有优异抑制作用的化合物（IV）的血液水平和抗凝血作用达到足以表达其药理作用的水平 。 因此，本发明的化合物可用作由血栓形成引起的疾病的治疗和/或预防剂。

公开(公告)号：US20130053563A1

公开(公告)日：2013-02-28

申请号：US13695665

申请日：2011-05-18

申请人： Richard Clark ,  Fumiyoshi Matsuura ,  Masanobu Shinoda ,  Shinsuke Hirota ,  Kazunobu Kira ,  Hiroshi Azuma ,  Atsushi Takemura ,  So Yasui ,  Kazutomi Kusano ,  Masaki Mikamoto ,  Takao Omae

发明人： Richard Clark ,  Fumiyoshi Matsuura ,  Masanobu Shinoda ,  Shinsuke Hirota ,  Kazunobu Kira ,  Hiroshi Azuma ,  Atsushi Takemura ,  So Yasui ,  Kazutomi Kusano ,  Masaki Mikamoto ,  Takao Omae

IPC分类号： C07D403/04 ,  C07D401/14

CPC分类号： C07D401/14 ,  C07D403/04

摘要： By oral administration of a compound represented by the following Formula (I): the blood level of Compound (IV): which has an excellent inhibitory action against blood coagulation factor VIIa and the anticoagulant action, reaches a level sufficient for expression of its pharmacological actions. Therefore, the compound of the present invention is useful as a therapeutic and/or prophylactic agent for diseases caused by thrombus formation.

摘要翻译： 通过口服给药由下式（I）表示的化合物：对血液凝固因子VIIa具有优异抑制作用的化合物（IV）的血液水平和抗凝血作用达到足以表达其药理作用的水平 。 因此，本发明的化合物可用作由血栓形成引起的疾病的治疗和/或预防剂。